CIM
IART icon

Contravisory Investment Management’s Integra LifeSciences IART Stock Holding History

Contravisory Investment Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,590
Closed -$220K – 385
2017
Q4 		$220K Sell
4,590
-285
-6% -$13.9K 0.08% 131
2017
Q3 		$246K Buy
+4,875
New +$250K 0.09% 127

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Contravisory Investment Management's IART Position: Q1 2018 in Review

Contravisory Investment Management sold out of Integra LifeSciences (IART) in Q1 2018, closing a stake of 4,590 shares — an estimated $220K sold.

Contravisory Investment Management first reported a position in IART in Q3 2017 and held it in 2 quarters. The position peaked at $246K in Q3 2017. 235 funds tracked by Wall St. Rank hold IART as of Q1 2018.

  • Contravisory Investment Management reported no remaining Integra LifeSciences position as of Q1 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 4,590 Integra LifeSciences shares in Q1 2018, an estimated $220K.
  • Contravisory Investment Management first reported a position in Integra LifeSciences in Q3 2017 and held it in 2 quarters.
  • Contravisory Investment Management's Integra LifeSciences position peaked at $246K in Q3 2017.
  • 235 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2018.

Based on Contravisory Investment Management's 13F filing for Q1 2018, filed 9 Apr 2018.